Тарасова Л.В., Трухан Д.И. Болезни кишечника. Клиника, диагностика и лечение. СПб.; 2013. 144 с.
Харитонова Л.А., Григорьев К.И., Борзакова С.Н. Микробиота человека: как новая научная парадигма меняет медицинскую практику. Экспериментальная и клиническая гастроэнтерология. 2019;(1):55–63. https://doi.org/10.31146/1682-8658-ecg-161-1-55-63..
DOI: 10.31146/1682-8658-ecg-161-1-55-63
Юдина Ю.В., Корсунский А.А., Аминова А.И., Абдуллаева Г.Д., Продвус А.П. Микробиота кишечника как отдельная система организма. Доказательная гастроэнтерология. 2019;(4):36–43. https://doi.org/10.17116/dokgastro2019804-05136..
DOI: 10.17116/dokgastro2019804-05136
Кайбышева В.О., Жарова М.Е., Филимендикова К.Ю., Никонов Е.Л. Микробиом человека: возрастные изменения и функции. Доказательная гастроэнтерология. 2020;(2):42–55. https://doi.org/10.17116/dokgastro2020902142..
DOI: 10.17116/dokgastro2020902142
Комарова О.Н., Хавкин А.И. Взаимосвязь стресса, иммунитета и кишечной микробиоты. Педиатрическая фармакология. 2020;(1):18–24. https://doi.org/10.15690/pf.v17i1.2078..
DOI: 10.15690/pf.v17i1.2078
Ардатская М.Д., Бельмер С.В., Добрица В.П., Захаренко С.М., Лазебник Л.Б., Минушкин О.Н. и др. Дисбиоз (дисбактериоз) кишечника: современное состояние проблемы, комплексная диагностика и лечебная коррекция. Экспериментальная и клиническая гастроэнтерология. 2015;(5):13–50. Режим доступа: https://cyberleninka.ru/article/n/disbioz-disbakterioz-kishechnika-sovremennoe-sostoyanie-problemy-kompleksnaya-diagnostika-i-lechebnaya-korrektsiya.https://cyberleninka.ru/article/n/disbioz-disbakterioz-kishechnika-sovremennoe-sostoyanie-problemy-kompleksnaya-diagnostika-i-lechebnaya-korrektsiya
Ардатская М.Д., Бельмер С.В., Добрица В.П., Захаренко С.М., Лазебник Л.Б., Минушкин О.Н. и др. Дисбиоз (дисбактериоз) кишечника: современное состояние проблемы, комплексная диагностика и лечебная коррекция. Экспериментальная и клиническая гастроэнтерология. 2015;(5):13–50. Режим доступа: https://cyberleninka.ru/article/n/disbioz-disbakterioz-kishechnika-sovremennoe-sostoyanie-problemy-kompleksnaya-diagnostika-i-lechebnaya-korrektsiya.https://cyberleninka.ru/article/n/disbioz-disbakterioz-kishechnika-sovremennoe-sostoyanie-problemy-kompleksnaya-diagnostika-i-lechebnaya-korrektsiya
Трухан Д.И., Филимонов С.Н. Дифференциальный диагноз основных гастроэнтерологических синдромов и симптомов. М.; 2016. 168 с.
Трухан Д.И., Филимонов С.Н. Заболевания кишечника: клиника, диагностика и лечение. Новокузнецк; 2017. 223 с.
Bouhnik Y., Alain S., Attar A., Flourié B., Raskine L., Sanson-Le Pors M.J., Rambaud J.C. Bacterial populations contaminating the upper gut in patients with small intestinal bacterial overgrowth syndrome. Am J Gastroenterol. 1999;94(5):1327–1331. https://doi.org/10.1111/j.1572-0241.1999.01016.x..
DOI: 10.1111/j.1572-0241.1999.01016.x
Stein J.M., Schneider A.R. Bacterial overgrowth syndrome. Z Gastroenterol. 2007;45(7):620–628. https://doi.org/10.1055/s-2007-963045..
DOI: 10.1055/s-2007-963045
Quigley E.M. Small intestinal bacterial overgrowth: what it is and what it is not. Curr Opin Gastroenterol. 2014;30(2):141–146. https://doi.org/10.1097/MOG.0000000000000040..
DOI: 10.1097/MOG.0000000000000040
Guarner F., Khan A.G., Garisch J., Eliakim R., Gangl А., Thomson А. et al. Пробиотики и пребиотики. Глобальные практические рекомендации Всемирной гастроэнтерологической организации. 2008. 37 с. Режим доступа: https://www.worldgastroenterology.org/UserFiles/file/guide-lines/probiotics-and-prebiotics-russian-2017.pdf.https://www.worldgastroenterology.org/UserFiles/file/guide-lines/probiotics-and-prebiotics-russian-2017.pdf
Guarner F., Khan A.G., Garisch J., Eliakim R., Gangl А., Thomson А. et al. Пробиотики и пребиотики. Глобальные практические рекомендации Всемирной гастроэнтерологической организации. 2008. 37 с. Режим доступа: https://www.worldgastroenterology.org/UserFiles/file/guide-lines/probiotics-and-prebiotics-russian-2017.pdf.https://www.worldgastroenterology.org/UserFiles/file/guidelines/probiotics-and-prebiotics-russian-2017.pdf
Manzanares W., Lemieux M., Langlois P.L., Wischmeyer P.E. Probiotic and synbiotic therapy in critical illness: a systematic review and meta-analysis. Crit Care. 2016;19:262. https://doi.org/10.1186/s13054-016-1434-y..
DOI: 10.1186/s13054-016-1434-y
Sebastian Domingo J.J. Review of the role of probiotics in gastrointestinal diseases in adults. Gastroenterol Hepatol. 2017;40(6):417–429. https://doi.org/10.1016/j.gastrohep.2016.12.003..
DOI: 10.1016/j.gastrohep.2016.12.003
Hütt P., Shchepetova J., Lõivukene K., Kullisaar T., Mikelsaar M. Antagonistic activity of probiotic lactobacilli and bifidobacteria against entero- and uropathogens. J Appl Microbiol. 2006;100(6):1324–1332. https://doi.org/10.1111/j.1365-2672.2006.02857.x..
DOI: 10.1111/j.1365-2672.2006.02857.x
McFarland L.V. Meta-analysis of probiotics for the prevention of traveler’s diarrhea. Travel Med Infect Dis. 2007;5(2):97–105. https://doi.org/10.1016/j.tmaid.2005.10.003..
DOI: 10.1016/j.tmaid.2005.10.003
Singhi S.C., Baranwal A. Probiotic use in the critically ill. Indian J Pediatr. 2008;75(6):621–627. https://doi.org/10.1007/s12098-008-0119-1..
DOI: 10.1007/s12098-008-0119-1
Turroni F., Duranti S., Milani C., Lugli G.A., van Sinderen D., Ventura M. Bifidobacterium bifidum: A Key Member of the Early Human Gut Microbiota. Microorganisms. 2019;7(11):544. https://doi.org/10.3390/microorganisms7110544..
DOI: 10.3390/microorganisms7110544
Dongarrà M.L., Rizzello V., Muccio L., Fries W., Cascio A., Bonaccorsi I., Ferlazzo G. Mucosal immunology and probiotics. Curr Allergy Asthma Rep. 2013;13(1):19–26. https://doi.org/10.1007/s11882-012-0313-0..
DOI: 10.1007/s11882-012-0313-0
Arboleya S., Watkins C., Stanton C., Ross R.P. Gut Bifidobacteria Populations in Human Health and Aging. Front Microbiol. 2016;7:1204. https://doi.org/10.3389/fmicb.2016.01204..
DOI: 10.3389/fmicb.2016.01204
Kalyuzhin O.V., Afanasyev S.S., Bykov A.S. Probiotics as stimulators of immune response against pathogens in the respiratory tract. Ter Arkh. 2016;88(5):118–124. https://doi.org/10.17116/terarkh2016885118-124..
DOI: 10.17116/terarkh2016885118-124
Melli L.C., do Carmo-Rodrigues M.S., Araújo-Filho H.B., Solé D., de Morais M.B. Intestinal microbiota and allergic diseases: A systematic review. Allergol Immunopathol (Madr). 2016;44(2):177–188. https://doi.org/10.1016/j.aller.2015.01.013..
DOI: 10.1016/j.aller.2015.01.013
Tan-Lim C.S.C., Esteban-Ipac N.A.R., Mantaring J.B.V. 3rd, Chan Shih Yen E., Recto M.S.T., Sison O.T., Alejandria M.M. Comparative effectiveness of probiotic strains for the treatment of pediatric atopic dermatitis: A systematic review and network meta-analysis. Pediatr Allergy Immunol. 2021;32(1):124–136. https://doi.org/10.1111/pai.13305..
DOI: 10.1111/pai.13305
Xie C., Li J., Wang K., Li Q., Chen D. Probiotics for the prevention of antibiotic-associated diarrhoea in older patients: a systematic review. Travel Med Infect Dis. 2015;13(2):128–134. https://doi.org/10.1016/j.tmaid.2015.03.001..
DOI: 10.1016/j.tmaid.2015.03.001
McFarland L.V. Probiotics for the Primary and Secondary Prevention of C. difficile Infections: A Meta-analysis and Systematic Review. Antibiotics (Basel). 2015;4(2):160–178. https://doi.org/10.3390/antibiotics4020160..
DOI: 10.3390/antibiotics4020160
Hamilton-Miller J.M. The role of probiotics in the treatment and prevention of Helicobacter pylori infection. Int J Antimicrob Agents. 2003;22(4):360–366. https://doi.org/10.1016/s0924-8579(03)00153-5..
DOI: 10.1016/s0924-8579(03)00153-5
Cruchet S., Furnes R., Maruy A., Hebel E., Palacios J., Medina F. et al. The use of probiotics in pediatric gastroenterology: a review of the literature and recommendations by Latin-American experts. Paediatr Drugs. 2015;17(3):199–216. https://doi.org/10.1007/s40272-015-0124-6..
DOI: 10.1007/s40272-015-0124-6
Feng J.R., Wang F., Qiu X., McFarland L.V., Chen P.F., Zhou R. et al. Efficacy and safety of probiotic-supplemented triple therapy for eradication of Helicobacter pylori in children: a systematic review and network meta-analysis. Eur J Clin Pharmacol. 2017;73(10):1199–1208. https://doi.org/10.1007/s00228-017-2291-6..
DOI: 10.1007/s00228-017-2291-6
Eslami M., Yousefi B., Kokhaei P., Jazayeri Moghadas A., Sadighi Moghadam B., Arabkari V., Niazi Z. Are probiotics useful for therapy of Helicobacter pylori diseases? Comp Immunol Microbiol Infect Dis. 2019;64:99–108. https://doi.org/10.1016/j.cimid.2019.02.010..
DOI: 10.1016/j.cimid.2019.02.010
Martínez-Martínez M.I., Calabuig-Tolsá R., Cauli O. The effect of probiotics as a treatment for constipation in elderly people: A systematic review. Arch Gerontol Geriatr. 2017;71:142–149. https://doi.org/10.1016/j.arch-ger.2017.04.004..
DOI: 10.1016/j.arch-ger.2017.04.004
Ortiz-Lucas M., Tobías A., Saz P., Sebastián J.J. Effect of probiotic species on irritable bowel syndrome symptoms: A bring up to date meta-analysis. Rev Esp Enferm Dig. 2013;105(1):19–36. https://doi.org/10.4321/s1130-01082013000100005..
DOI: 10.4321/s1130-01082013000100005
Шульпекова Ю.О., Курбатова А.А., Седова А.В. Запор функционального происхождения. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2017;(5):105–112. Режим доступа: https://www.gastro-j.ru/jour/article/view/186/160.https://www.gastro-j.ru/jour/article/view/186/160
Шульпекова Ю.О., Курбатова А.А., Седова А.В. Запор функционального происхождения. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2017;(5):105–112. Режим доступа: https://www.gastro-j.ru/jour/article/view/186/160.https://www.gastro-j.ru/jour/article/view/186/160
Sela D.A. Bifidobacterial utilization of human milk oligosaccharides. Int J Food Microbiol. 2011;149(1):58–64. https://doi.org/10.1016/j.ijfoodmicro.2011.01.025..
DOI: 10.1016/j.ijfoodmicro.2011.01.025
Chichlowski M., Shah N., Wampler J.L., Wu S.S., Vanderhoof J.A. Bifidobacterium longum Subspecies infantis (B. infantis) in Pediatric Nutrition: Current State of Knowledge. Nutrients. 2020;12(6):1581. https://doi.org/10.3390/nu12061581..
DOI: 10.3390/nu12061581
Underwood M.A., German J.B., Lebrilla C.B., Mills D.A. Bifidobacterium longum subspecies infantis: champion colonizer of the infant gut. Pediatr Res. 2015;77(1–2):229–235. https://doi.org/10.1038/pr.2014.156..
DOI: 10.1038/pr.2014.156
Ganguli K., Walker W.A. Probiotics in the prevention of necrotizing enterocolitis. J Clin Gastroenterol. 2011;(45 Suppl.):S133–138. https://doi.org/10.1097/MCG.0b013e318228b799..
DOI: 10.1097/MCG.0b013e318228b799
Ritchie M.L., Romanuk T.N. A meta-analysis of probiotic efficacy for gastrointestinal diseases. PLoS ONE. 2012;7(4):e34938. https://doi.org/10.1371/journal.pone.0034938..
DOI: 10.1371/journal.pone.0034938
Kutylowksi J., Yahia N. Types, Frequency, Duration, and Dosage of Probiotics to Prevent Necrotizing Enterocolitis in Preterm Infants Among Countries. Adv Neonatal Care. 2019;19(3):188–197. https://doi.org/10.1097/ANC.0000000000000605..
DOI: 10.1097/ANC.0000000000000605
Brenner D.M., Moeller M.J., Chey W.D., Schoenfeld P.S. The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review. Am J Gastroenterol. 2009;104(4):1033–1049; quiz 1050. Available at: https://pubmed.ncbi.nlm.nih.gov/19277023.https://pubmed.ncbi.nlm.nih.gov/19277023
Brenner D.M., Moeller M.J., Chey W.D., Schoenfeld P.S. The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review. Am J Gastroenterol. 2009;104(4):1033–1049; quiz 1050. Available at: https://pubmed.ncbi.nlm.nih.gov/19277023.https://pubmed.ncbi.nlm.nih.gov/19277023
Schmulson M., Chang L. Review article: the treatment of functional abdominal bloating and distension. Aliment Pharmacol Ther. 2016;63(Suppl. 1):S25–S26. https://doi.org/10.1111/j.1365-2036.2011.04637.x..
DOI: 10.1111/j.1365-2036.2011.04637.x
Giannetti E., Staiano A. Probiotics for Irritable Bowel Syndrome: Clinical Data in Children. J Pediatr Gastroenterol Nutr. 2016;(63 Suppl. 1):S25–26. Available at: https://pubmed.ncbi.nlm.nih.gov/27380595.https://pubmed.ncbi.nlm.nih.gov/27380595
Giannetti E., Staiano A. Probiotics for Irritable Bowel Syndrome: Clinical Data in Children. J Pediatr Gastroenterol Nutr. 2016;(63 Suppl. 1):S25–26. Available at: https://pubmed.ncbi.nlm.nih.gov/27380595.https://pubmed.ncbi.nlm.nih.gov/27380595
Yuan F., Ni H., Asche C.V., Kim M., Walayat S., Ren J. Efficacy of Bifidobacterium infantis 35624 in patients with irritable bowel syndrome: a meta-analysis. Curr Med Res Opin. 2017;33(7):1191–1197. https://doi.org/10.1080/03007995.2017.1292230..
DOI: 10.1080/03007995.2017.1292230
Groeger D., O’Mahony L., Murphy E.F., Bourke J.F., Dinan T.G., Kiely B. et al. Bifidobacterium infantis 35624 modulates host inflammatory processes beyond the gut. Gut Microbes. 2013;4(4):325–339. https://doi.org/10.4161/gmic.25487..
DOI: 10.4161/gmic.25487
Konieczna P., Groeger D., Ziegler M., Frei R., Ferstl R., Shanahan F. et al. Bifidobacterium infantis 35624 administration induces Foxp3 T regulatory cells in human peripheral blood: potential role for myeloid and plasmacytoid dendritic cells. Gut. 2012;61(3):354–366. https://doi.org/10.1136/gutjnl-2011-300936..
DOI: 10.1136/gutjnl-2011-300936
Goldstein E.J., Tyrrell K.L., Citron D.M. Lactobacillus species: taxonomic complexity and controversial susceptibilities. Clin Infect Dis. 2015;60(Suppl. 2):S98–S107. https://doi.org/10.1093/cid/civ072..
DOI: 10.1093/cid/civ072
Hill D., Sugrue I., Tobin C., Hill C., Stanton C., Ross R.P. The Lactobacillus casei Group: History and Health Related Applications. Front Microbiol. 2018;9:2107. https://doi.org/10.3389/fmicb.2018.02107..
DOI: 10.3389/fmicb.2018.02107
Ashraf R., Shah N.P. Immune system stimulation by probiotic microorganisms. Crit Rev Food Sci Nutr. 2014;54(7):938–956. https://doi.org/10.1080/10408398.2011.619671..
DOI: 10.1080/10408398.2011.619671
Goldstein E.J.C., Johnson S.J., Maziade P.J., Evans C.T., Sniffen J.C., Millette M., McFarland L.V. Probiotics and prevention of Clostridium difficile infection. Anaerobe. 2017;45:114–119. https://doi.org/10.1016/j.anaerobe.2016.12.007..
DOI: 10.1016/j.anaerobe.2016.12.007
Blaabjerg S., Artzi D.M., Aabenhus R. Probiotics for the Prevention of Antibiotic-Associated Diarrhea in Outpatients-A Systematic Review and Meta-Analysis. Antibiotics (Basel). 2017;6(4):21. https://doi.org/10.3390/antibiotics6040021..
DOI: 10.3390/antibiotics6040021
Valdés-Varela L., Gueimonde M., Ruas-Madiedo P. Probiotics for Prevention and Treatment of Clostridium difficile Infection. Adv Exp Med Biol. 2018;1050:161–176. https://doi.org/10.1007/978-3-319-72799-8_10..
DOI: 10.1007/978-3-319-72799-8_10
McFarland L.V., Goh S. Are probiotics and prebiotics effective in the prevention of travellers’ diarrhea: A systematic review and meta-analysis. Travel Med Infect Dis. 2019;27:11–19. https://doi.org/10.1016/j.tmaid.2018.09.007..
DOI: 10.1016/j.tmaid.2018.09.007
Ng Q.X., Peters C., Venkatanarayanan N., Goh Y.Y., Ho C.Y.X., Yeo W.S. Use of Lactobacillus spp. to prevent recurrent urinary tract infections in females. Med Hypotheses. 2018;114:49–54. https://doi.org/10.1016/j.mehy.2018.03.001..
DOI: 10.1016/j.mehy.2018.03.001
Amaral M.A., Guedes G.H.B.F., Epifanio M., Wagner M.B., Jones M.H., Mattiello R. Network meta-analysis of probiotics to prevent respiratory infections in children and adolescents. Pediatr Pulmonol. 2017;52(6):833–843. https://doi.org/10.1002/ppul.23643..
DOI: 10.1002/ppul.23643
Capurso L. Thirty Years of Lactobacillus rhamnosus GG: A Review. J Clin Gastroenterol. 2019;53(1 Suppl.):S1–S41. https://doi.org/10.1097/MCG.0000000000001170..
DOI: 10.1097/MCG.0000000000001170
Wojtyniak K., Szajewska H. Systematic review: probiotics for functional constipation in children. Eur J Pediatr. 2017;176(9):1155–1162. https://doi.org/10.1007/s00431-017-2972-2..
DOI: 10.1007/s00431-017-2972-2
Hojsak I. Probiotics in Functional Gastrointestinal Disorders. Adv Exp Med Biol. 2019;1125:121–137. https://doi.org/10.1007/5584_2018_321..
DOI: 10.1007/5584_2018_321
McFarland L.V., Huang Y., Wang L., Malfertheiner P. Systematic review and meta-analysis: Multi-strain probiotics as adjunct therapy for Helicobacter pylori eradication and prevention of adverse events. United European Gastroenterol J. 2016;4(4):546–561. https://doi.org/10.1177/2050640615617358..
DOI: 10.1177/2050640615617358
Han Y.M., Park J.M., Jeong M., Yoo J.H., Kim W.H., Shin S.R. et al. Dietary, non-microbial intervention to prevent Helicobacter pylori-associated gastric diseases. Ann Transl Med. 2015;3(9):122. https://doi.org/10.3978/j.issn.2305-5839.2015.03.50..
DOI: 10.3978/j.issn.2305-5839.2015.03.50
Malfertheiner P., Megraud F., O’Morain C.A., Gisbert J.P., Kuipers E.J., Axon A.T. et al. Management of Helicobacter pylori infection – the Maastricht V/Florence Consensus Report. Gut. 2017;66(1):6–30. https://doi.org/10.1136/gutjnl-2016-312288..
DOI: 10.1136/gutjnl-2016-312288
Tong J.L., Ran Z.H., Shen J., Zhang C.X., Xiao S.D. Meta-analysis: the effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther. 2007;25(2):155–168. https://doi.org/10.1111/j.1365-2036.2006.03179.x..
DOI: 10.1111/j.1365-2036.2006.03179.x
Wang Z.H., Gao Q.Y., Fang J.Y. Meta-analysis of the efficacy and safety of Lactobacillus-containing and Bifidobacterium-containing probiotic compound preparation in Helicobacter pylori eradication therapy. J Clin Gastroenterol. 2013;47(1):25-32. https://doi.org/10.1097/MCG.0b013e318266f6cf..
DOI: 10.1097/MCG.0b013e318266f6cf
Zheng X., Lyu L., Mei Z. Lactobacillus-containing probiotic supplementation increases Helicobacter pylori eradication rate: evidence from a meta-analysis. Rev Esp Enferm Dig. 2013;105(8):445–453. https://doi.org/10.4321/s1130-01082013000800002..
DOI: 10.4321/s1130-01082013000800002
Zhu R., Chen K., Zheng Y.-Y., Zhang H.W., Wang J.S. Xia Y.J. et al. Meta-analysis of the efficacy of probiotics in Helicobacter pylori eradication therapy. World J Gastroenterol. 2014;20(47):18013–18021. https://doi.org/10.3748/wjg.v20.i47.18013..
DOI: 10.3748/wjg.v20.i47.18013
Dang Y., Reinhardt J.D., Zhou X., Zhang G. The effect of probiotics supplementation on Helicobacter pylori eradication rates and side effects during eradication therapy: a meta-analysis. PloS ONE. 2014;9(11):e111030. https://doi.org/10.1371/journal.pone.0111030..
DOI: 10.1371/journal.pone.0111030
Lv Z., Wang B., Zhou X., Wang F., Xie Y., Zheng H., Lv N. Efficacy and safety of probiotics as adjuvant agents for Helicobacter pylori infection: a meta-analysis. Exp Ther Med. 2015;9(3):707–716. https://doi.org/10.3892/etm.2015.2174..
DOI: 10.3892/etm.2015.2174
Zhang M-M., Qian W., Qin Y-Y., He J., Zhou J.H. Probiotics in Helicobacter pylori eradication therapy: a systematic review and meta-analysis. World J Gastro enterol. 2015;21(14):4345–4357. https://doi.org/10.3748/wjg.v21.i14.4345..
DOI: 10.3748/wjg.v21.i14.4345
Arrieta M.C., Bistritz L., Meddings J.B. Alterations in intestinal permeability. Gut. 2006;55(10):1512–1520. https://doi.org/10.1136/gut.2005.085373..
DOI: 10.1136/gut.2005.085373
Turner J.R. Intestinal mucosal barrier function in health and disease. Nat Rev Immunol. 2009;9(11):799–809. https://doi.org/10.1038/nri2653..
DOI: 10.1038/nri2653
Odenwald M.A., Turner J.R. Intestinal permeability defects: Is it time to treat? Clin Gastroenterol Hepatol. 2013;11(9):1075–1083. https://doi.org/10.1016/j.cgh.2013.07.001..
DOI: 10.1016/j.cgh.2013.07.001
Graziani C., Talocco C., De Sire R., Petito V., Lopetuso L.R., Gervasoni J. et al. Intestinal Permeability in Physiological and Pathological Conditions: Major Determinants and Assessment Modalities. Eur Rev Med Pharmacol Sci. 2019;23(2):795–810. https://doi.org/10.26355/eurrev_201901_16894..
DOI: 10.26355/eurrev_201901_16894
Sturgeon C., Fasano A. Zonulin, a regulator of epithelial and endothelial barrier functions, and its involvement in chronic inflammatory diseases. Tissue Barriers. 2016;4(4):e1251384. https://doi.org/10.1080/21688370.2016.1251384..
DOI: 10.1080/21688370.2016.1251384
Matysiak-Budnik T., Heyman M., Megraud F. Review article: rebamipide and the digestive epithelial barrier. Aliment Pharmacol Ther. 2003;18(Suppl. 1):55–62. https://doi.org/10.1046/j.1365-2036.18.s1.6.x..
DOI: 10.1046/j.1365-2036.18.s1.6.x
Fukui H. Increased Intestinal Permeability and Decreased Barrier Function: Does It Really Influence the Risk of Inflammation? Inflamm Intest Dis. 2016;1(3):135–145. https://doi.org/10.1159/000447252..
DOI: 10.1159/000447252
Otani K., Tanigawa T., Watanabe T., Shimada S., Nadatani Y., Nagami Y. et al. Microbiota Plays a Key Role in Non-Steroidal Anti-Inflammatory Drug-Induced Small Intestinal Damage. Digestion. 2017;95(1):22–28. https://doi.org/10.1159/000452356..
DOI: 10.1159/000452356
Wells J.M. Immunomodulatory mechanisms of lactobacilli. Microb Cell Fact. 2011;10 Suppl. 1 (Suppl. 1):S17. https://doi.org/10.1186/1475-2859-10-S1-S17..
DOI: 10.1186/1475-2859-10-S1-S17
Cong Y., Feng T., Fujihashi K., Schoeb T.R., Elson C.O. A dominant, coordinated T regulatory cell-IgA response to the intestinal microbiota. Proc Natl Acad Sci USA. 2009;106(46):19256–19261. https://doi.org/10.1073/pnas.0812681106..
DOI: 10.1073/pnas.0812681106
Smith P.M., Garrett W.S. The gut microbiota and mucosal T cells. Front Microbiol. 2011;2:111. https://doi.org/10.3389/fmicb.2011.00111..
DOI: 10.3389/fmicb.2011.00111
Taverniti V., Guglielmetti S. The immunomodulatory properties of probiotic microorganisms beyond their viability (ghost probiotics: proposal of paraprobiotic concept). Genes Nutr. 2011;6(3):261–274. https://doi.org/10.1007/s12263-011-0218-x..
DOI: 10.1007/s12263-011-0218-x
Калюжин О.В. Пробиотические штаммы лактобацилл как иммуномодуляторы: в фокусе – Lactobacillus rhamnosus GG. Медицинский совет. 2017;(9):108–115. https://doi.org/10.21518/2079-701X-2017-9-108-115..
DOI: 10.21518/2079-701X-2017-9-108-115
Abt M.C., Osborne L.C., Monticelli L.A., Doering T.A., Alenghat T., Sonnenberg G.F. et al. Commensal bacteria calibrate the activation threshold of innate antiviral immunity. Immunity. 2012;37(1):158–170. https://doi.org/10.1016/j.immuni.2012.04.011..
DOI: 10.1016/j.immuni.2012.04.011
Булгакова В.А., Балаболкин И.И., Ушакова В.В. Современное состояние проблемы часто болеющих детей. Педиатрическая фармакология. 2007;(2): 48–52. Режим доступа: https://www.pedpharma.ru/jour/article/view/643.https://www.pedpharma.ru/jour/article/view/643
Булгакова В.А., Балаболкин И.И., Ушакова В.В. Современное состояние проблемы часто болеющих детей. Педиатрическая фармакология. 2007;(2): 48–52. Режим доступа: https://www.pedpharma.ru/jour/article/view/643.https://www.pedpharma.ru/jour/article/view/643
Трухан Д.И., Викторова И.А. Коррекция нарушений кишечного микробиоценоза в аспекте профилактики респираторных инфекций дыхательных путей: возможности Lactobacillus rhamnosus GG. Consilium Medicum. 2018;(2):39–44. Режим доступа: https://omnidoctor.ru/library/izdaniya-dlya-vrachey/consilium-medicum/cm2018/gastro2018_pril/gastro2018_2_pril/korrektsiya-narusheniy-kishechnogo-mikrobiotsenoza-v-aspekte-profilaktiki-respiratornykh-infektsiy-d/.https://omnidoctor.ru/library/izdaniya-dlya-vrachey/consilium-medicum/cm2018/gastro2018_pril/gastro2018_2_pril/korrektsiya-narusheniy-kishechnogo-mikrobiotsenoza-v-aspekte-profilaktiki-respiratornykh-infektsiy-d/
Трухан Д.И., Викторова И.А. Коррекция нарушений кишечного микробиоценоза в аспекте профилактики респираторных инфекций дыхательных путей: возможности Lactobacillus rhamnosus GG. Consilium Medicum. 2018;(2):39–44. Режим доступа: https://omnidoctor.ru/library/izdaniya-dlya-vrachey/consilium-medicum/cm2018/gastro2018_pril/gastro2018_2_pril/korrektsiya-narusheniy-kishechnogo-mikrobiotsenoza-v-aspekte-profilaktiki-respiratornykh-infektsiy-d/.https://omnidoctor.ru/library/izdaniya-dlya-vrachey/consilium-medicum/cm2018/gastro2018_pril/gastro2018_2_pril/korrektsiya-narusheniy-kishechnogo-mikrobiotsenoza-v-aspekte-profilaktiki-respiratornykh-infektsiy-d/
Гриневич В.Б., Губонина И.В., Дощицин В.Л., Котовская Ю.В., Кравчук Ю.А., Педь В.И. и др. Особенности ведения коморбидных пациентов в период пандемии новой коронавирусной инфекции (COVID-19). Национальный Консенсус 2020. Кардиоваскулярная терапия и профилактика. 2020;(4):2630. https://doi.org/10.15829/1728-8800-2020-2630..
DOI: 10.15829/1728-8800-2020-2630
Княжеская Н.П. Иммунотерапия хронических заболеваний легких. Consilium Medicum. 2014;(3):42–48. Режим доступа: https://omnidoctor.ru/library/izdaniya-dlya-vrachey/consilium-medicum/cm2014/cm2014_3_pulmo/immunoterapiya-khronicheskikh-zabolevaniy-legkikh/.https://omnidoctor.ru/library/izdaniya-dlya-vrachey/consilium-medicum/cm2014/cm2014_3_pulmo/immunoterapiya-khronicheskikh-zabolevaniy-legkikh/
Княжеская Н.П. Иммунотерапия хронических заболеваний легких. Consilium Medicum. 2014;(3):42–48. Режим доступа: https://omnidoctor.ru/library/izdaniya-dlya-vrachey/consilium-medicum/cm2014/cm2014_3_pulmo/immunoterapiya-khronicheskikh-zabolevaniy-legkikh/.https://omnidoctor.ru/library/izdaniya-dlya-vrachey/consilium-medicum/cm2014/cm2014_3_pulmo/immunoterapiya-khronicheskikh-zabolevaniy-legkikh/
Johnstone J., Meade M., Marshall J., Heyland D.K., Surette M.G., Bowdish D.M. et al. Probiotics: Prevention of Severe Pneumonia and Endotracheal Colonization Trial-PROSPECT: protocol for a feasibility randomized pilot trial. Pilot Feasibility Stud. 2015;1:19. https://doi.org/10.1186/s40814-015-0013-3..
DOI: 10.1186/s40814-015-0013-3
van den Broek M.F.L., De Boeck I., Claes I.J.J., Nizet V., Lebeer S. Multifactorial inhibition of lactobacilli against the respiratory tract pathogen Moraxella catarrhalis. Benef Microbes. 2018;9(3):429–439. https://doi.org/10.3920/BM2017.0101..
DOI: 10.3920/BM2017.0101
Kalima K., Lehtoranta L., He L., Pitkäniemi J., Lundell R., Julkunen I. et al. Probiotics and respiratory and gastrointestinal tract infections in Finnish military conscripts – a randomised placebo-controlled double-blinded study. Benef Microbes. 2016;7(4):463–471. https://doi.org/10.3920/BM2015.0172..
DOI: 10.3920/BM2015.0172
Tapiovaara L., Kumpu M., Mäkivuokko H., Waris M., Korpela R., Pitkäranta A., Winther B. Human rhinovirus in experimental infection after peroral Lactobacillus rhamnosus GG consumption, a pilot study. Int Forum Allergy Rhinol. 2016;6(8):848–853. https://doi.org/10.1002/alr.21748..
DOI: 10.1002/alr.21748
Wang B., Hylwka T., Smieja M., Surrette M., Bowdish D.M.E., Loeb M. Probiotics to Prevent Respiratory Infections in Nursing Homes: A Pilot Randomized Controlled Trial. J Am Geriatr Soc. 2018;66(7):1346–1352. https://doi.org/10.1111/jgs.15396..
DOI: 10.1111/jgs.15396
Laursen R.P., Hojsak I. Probiotics for respiratory tract infections in children attending day care centers-a systematic review. Eur J Pediatr. 2018;177(7):979–994. https://doi.org/10.1007/s00431-018-3167-1..
DOI: 10.1007/s00431-018-3167-1
Youssef M., Ahmed H.Y., Zongo A., Korin A., Zhan F., Hady E. et al. Probiotic Supplements: Their Strategies in the Therapeutic and Prophylactic of Human Life-Threatening Diseases. Int J Mol Sci. 2021;22(20):11290. https://doi.org/10.3390/ijms222011290..
DOI: 10.3390/ijms222011290
Manzoor S., Wani S.M., Ahmad Mir S., Rizwan D. Role of probiotics and prebiotics in mitigation of different diseases. Nutrition. 2022;96:111602. https://doi.org/10.1016/j.nut.2022.111602..
DOI: 10.1016/j.nut.2022.111602
Roy K., Agarwal S., Banerjee R., Paul M.K., Purbey P.K. COVID-19 and gut immunomodulation. World J Gastroenterol. 2021;27(46):7925–7942. https://doi.org/10.3748/wjg.v27.i46.7925..
DOI: 10.3748/wjg.v27.i46.7925
Venegas-Borsellino C., Sankararaman S., Roche K., Burns J., Landis R.M. Impact of COVID-19 on the Intestinal Microbiome. Curr Nutr Rep. 2021;10(4):300–306. https://doi.org/10.1007/s13668-021-00375-z..
DOI: 10.1007/s13668-021-00375-z
Skrajnowska D., Brumer M., Kankowska S., Matysek M., Miazio N., Bobrowska-Korczak B. Covid 19: Diet Composition and Health. Nutrients. 2021;13(9):2980. https://doi.org/10.3390/nu13092980..
DOI: 10.3390/nu13092980
Трухан Д.И., Давыдов Е.Л. Место и роль терапевта и врача общей практики в курации коморбидных пациентов в период пандемии новой коронавирусной инфекции (COVID-19): акцент на неспецифическую профилактику. Фарматека. 2021;(10):34–45. https://doi.org/10.18565/pharmateca.2021.13.44-53..
DOI: 10.18565/pharmateca.2021.13.44-53
Трухан Д.И., Давыдов Е.Л., Чусова Н.А. Нутрицевтики в профилактике, лечении и на этапе реабилитации после новой коронавирусной инфекции (COVID-19). Клинический разбор в общей медицине. 2021;(7):21–34. https://doi.org/10.47407/kr2021.2.7.00085..
DOI: 10.47407/kr2021.2.7.00085
Трухан Д.И., Филимонов С.Н. Дифференциальный диагноз основных симптомов и синдромов при заболеваниях желудочнокишечного тракта. Новокузнецк; 2022. 234 с. Режим доступа: https://www.elibrary.ru/item.asp?id=48177755.https://www.elibrary.ru/item.asp?id=48177755
Трухан Д.И., Филимонов С.Н. Дифференциальный диагноз основных симптомов и синдромов при заболеваниях желудочнокишечного тракта. Новокузнецк; 2022. 234 с. Режим доступа: https://www.elibrary.ru/item.asp?id=48177755.https://www.elibrary.ru/item.asp?id=48177755
Jabczyk M., Nowak J., Hudzik B., Zubelewicz-Szkodzińska B. Diet, Probiotics and Their Impact on the Gut Microbiota during the COVID-19 Pandemic. Nutrients. 2021;13(9):3172. https://doi.org/10.3390/nu13093172..
DOI: 10.3390/nu13093172
Di Renzo L., Gualtieri P., Pivari F., Soldati L., Attinà A., Leggeri C. et al. COVID-19: Is there a role for immunonutrition in obese patient? J Transl Med. 2020;18(1):415. https://doi.org/10.1186/s12967-020-02594-4..
DOI: 10.1186/s12967-020-02594-4
Majewski S., Piotrowski W. Pulmonary manifestations of inflammatory bowel disease. Arch Med Sci. 2015;11(6):1179–1188. https://doi.org/10.5114/aoms.2015.56343..
DOI: 10.5114/aoms.2015.56343
Симаненков В.И., Маев И.В., Ткачева О.Н, Алексеенко С.А., Андреев Д.Н., Бордин Д.С. и др. Синдром повышенной эпителиальной проницаемости в клинической практике. Мультидисциплинарный национальный консенсус. Кардиоваскулярная терапия и профилактика. 2021;(1):2758. https://doi.org/10.15829/1728-8800-2021-2758..
DOI: 10.15829/1728-8800-2021-2758
Трухан Д.И., Иванова Д.С. Роль и место синдрома повышенной эпителиальной проницаемости в развитии сердечно-сосудистых и бронхолегочных заболеваний: теоретические и практические аспекты применения ребамипида. Фарматека. 2021;(5):115–126. https://doi.org/10.18565/pharmateca.2021.5.115-126..
DOI: 10.18565/pharmateca.2021.5.115-126
Khan A.A., Singh H., Bilal M., Ashraf M.T. Microbiota, probiotics and respiratory infections: the three musketeers can tip off potential management of COVID-19. Am J Transl Res. 2021;13(10):10977–10993. Available at: https://pubmed.ncbi.nlm.nih.gov/34786037.https://pubmed.ncbi.nlm.nih.gov/34786037
Khan A.A., Singh H., Bilal M., Ashraf M.T. Microbiota, probiotics and respiratory infections: the three musketeers can tip off potential management of COVID-19. Am J Transl Res. 2021;13(10):10977–10993. Available at: https://pubmed.ncbi.nlm.nih.gov/34786037.https://pubmed.ncbi.nlm.nih.gov/34786037
Konturek P.C. How does COVID-19 affect intestinal microbiota? MMW Fortschr Med. 2021;163(Suppl. 5):17–20. https://doi.org/10.1007/s15006-021-0200-5..
DOI: 10.1007/s15006-021-0200-5
Baradaran Ghavami S., Pourhamzeh M., Farmani M., Raftar S.K.A., Shahrokh S., Shpichka A. et al. Cross-talk between immune system and microbiota in COVID-19. Expert Rev Gastroenterol Hepatol. 2021;15(11):1281–1294. https://doi.org/10.1080/17474124.2021.1991311..
DOI: 10.1080/17474124.2021.1991311
Xavier-Santos D., Padilha M., Fabiano G.A., Vinderola G., Gomes Cruz A., Sivieri K., Costa Antunes A.E. Evidences and perspectives of the use of probiotics, prebiotics, synbiotics, and postbiotics as adjuvants for prevention and treatment of COVID-19: A bibliometric analysis and systematic review. Trends Food Sci Technol. 2022;120:174–192. https://doi.org/10.1016/j.tifs.2021.12.033..
DOI: 10.1016/j.tifs.2021.12.033
Wang H., Wang H., Sun Y., Ren Z., Zhu W., Li A., Cui G. Potential Associations Between Microbiome and COVID-19. Front Med (Lausanne). 2021;8:785496. https://doi.org/10.3389/fmed.2021.785496..
DOI: 10.3389/fmed.2021.785496
Mirashrafi S., Moravejolahkami A.R., Balouch Zehi Z., Hojjati Kermani M.A., Bahreini-Esfahani N., Haratian M. Et al. The efficacy of probiotics on virus titres and antibody production in virus diseases: A systematic review on recent evidence for COVID-19 treatment. Clin Nutr ESPEN. 2021;46:1–8. https://doi.org/10.1016/j.clnesp.2021.10.016..
DOI: 10.1016/j.clnesp.2021.10.016
Kasti A.N., Synodinou K.D., Pyrousis I.A., Nikolaki M.D., Triantafyllou K.D. Probiotics Regulating Inflammation via NLRP3 Inflammasome Modulation: A Potential Therapeutic Approach for COVID-19. Microorganisms. 2021;9(11):2376. https://doi.org/10.3390/microorganisms9112376..
DOI: 10.3390/microorganisms9112376
Akour A. Probiotics and COVID-19: is there any link? Lett Appl Microbiol. 2020;71(3):229–234. https://doi.org/10.1111/lam.13334..
DOI: 10.1111/lam.13334
Bottari B., Castellone V., Neviani E. Probiotics and Covid-19. Int J Food Sci Nutr. 2021;72(3):293–299. https://doi.org/10.1080/09637486.2020.1807475..
DOI: 10.1080/09637486.2020.1807475
Parisi G.F., Carota G., Castruccio Castracani C., Spampinato M., Manti S., Papale M. et al. Nutraceuticals in the Prevention of Viral Infections, including COVID-19, among the Pediatric Population: A Review of the Literature. Int J Mol Sci. 2021;22(5):2465. https://doi.org/10.3390/ijms22052465..
DOI: 10.3390/ijms22052465
Batista K.S., de Albuquerque J.G., Vasconcelos M.H.A., Bezerra M.L.R., da Silva Barbalho M.B., Pinheiro R.O., Aquino J.S. Probiotics and prebiotics: potential prevention and therapeutic target for nutritional management of COVID-19? Nutr Res Rev. 2021;1–18. https://doi.org/10.1017/S0954422421000317..
DOI: 10.1017/S0954422421000317
Angurana S.K., Bansal A. Probiotics and Coronavirus disease 2019: think about the link. Br J Nutr. 2021;126(10):1564–1570. https://doi.org/10.1017/S000711452000361X..
DOI: 10.1017/S000711452000361X
Hawryłkowicz V., Lietz-Kijak D., Kaźmierczak-Siedlecka K., Sołek-Pastuszka J., Stachowska L., Folwarski M. et al. Patient Nutrition and Probiotic Therapy in COVID-19: What Do We Know in 2021? Nutrients. 2021;13(10):3385. https://doi.org/10.3390/nu13103385..
DOI: 10.3390/nu13103385
Nayebi A., Navashenaq J.G., Soleimani D., Nachvak S.M. Probiotic supplementation: A prospective approach in the treatment of COVID-19. Nutr Health. 2021:2601060211049631. https://doi.org/10.1177/02601060211049631..
DOI: 10.1177/02601060211049631
Rozga M., Cheng F.W., Handu D. Effects of Probiotics in Conditions or Infections Similar to COVID-19 on Health Outcomes: An Evidence Analysis Center Scoping Review. J Acad Nutr Diet. 2021;121(9):1841–1854. https://doi.org/10.1016/j.jand.2020.07.016..
DOI: 10.1016/j.jand.2020.07.016
Szychowiak P., Villageois-Tran K., Patrier J., Timsit J.F., Ruppé É. The role of the microbiota in the management of intensive care patients. Ann Intensive Care. 2022;12(1):3. https://doi.org/10.1186/s13613-021-00976-5..
DOI: 10.1186/s13613-021-00976-5
Serek P., Oleksy-Wawrzyniak M. The Effect of Bacterial Infections, Probiotics and Zonulin on Intestinal Barrier Integrity. Int J Mol Sci. 2021;22(21):11359. https://doi.org/10.3390/ijms222111359..
DOI: 10.3390/ijms222111359
Peng J., Zhang M., Yao G., Kwok L.Y., Zhang W. Probiotics as Adjunctive Treatment for Patients Contracted COVID-19: Current Understanding and Future Needs. Front Nutr. 2021;8:669808. https://doi.org/10.3389/fnut.2021.669808..
DOI: 10.3389/fnut.2021.669808
Nguyen Q.V., Chong L.C., Hor Y.Y., Lew L.C., Rather I.A., Choi S.B. Role of Probiotics in the Management of COVID-19: A Computational Perspective. Nutrients. 2022;14(2):274. https://doi.org/10.3390/nu14020274..
DOI: 10.3390/nu14020274
Ivashkin V., Fomin V., Moiseev S., Brovko M., Maslennikov R., Ulyanin A. et al. Efficacy of a Probiotic Consisting of Lacticaseibacillus rhamnosus PDV 1705, Bifidobacterium bifidum PDV 0903, Bifidobacterium longum subsp. infantis PDV 1911, and Bifidobacterium longum subsp. longum PDV 2301 in the Treatment of Hospitalized Patients with COVID-19: a Randomized Controlled Trial. Probiotics Antimicrob Proteins. 2021;1–9. https://doi.org/10.1007/s12602-021-09858-5..
DOI: 10.1007/s12602-021-09858-5
Gutiérrez-Castrellón P., Gandara-Martí T., Abreu Y. Abreu A.T., NietoRufino C.D., López-Orduña E., Jiménez-Escobar I. et al. Probiotic improves symptomatic and viral clearance in Covid19 outpatients: a randomized, quadruple-blinded, placebo-controlled trial. Gut Microbes. 2022;14(1):2018899. https://doi.org/10.1080/19490976.2021.2018899..
DOI: 10.1080/19490976.2021.2018899
Kageyama Y., Nishizaki Y., Aida K., Yayama K., Ebisui T., Akiyama T., Nakamura T. Lactobacillus plantarum induces innate cytokine responses that potentially provide a protective benefit against COVID-19: A single-arm, double-blind, prospective trial combined with an in vitro cytokine response assay. Exp Ther Med. 2022;23(1):20. https://doi.org/10.3892/etm.2021.10942..
DOI: 10.3892/etm.2021.10942
Zhang L., Xu Z., Mak J.W.Y., Chow K.M., Lui G., Li T.C.M. et al. Gut microbiota-derived synbiotic formula (SIM01) as a novel adjuvant therapy for COVID-19: An open-label pilot study. J Gastroenterol Hepatol. 2022. https://doi.org/10.1111/jgh.15796..
DOI: 10.1111/jgh.15796
Alharbi K.S., Singh Y., Hassan Almalki W., Rawat S., Afzal O., Alfawaz Altamimi A.S. et al. Gut Microbiota Disruption in COVID-19 or Post-COVID Illness Association with severity biomarkers: A Possible Role of Pre / Probiotics in manipulating microflora. Chem Biol Interact. 2022;358:109898. https://doi.org/10.1016/j.cbi.2022.109898..
DOI: 10.1016/j.cbi.2022.109898
El-Sayed E.M., Ibrahim K.S. Ameliorating effects of probiotics on alterations in iron homeostasis and inflammation in COVID-19. Mol Biol Rep. 2022;1–11. https://doi.org/10.1007/s11033-022-07226-2..
DOI: 10.1007/s11033-022-07226-2
Rathi A., Jadhav S.B., Shah N. A Randomized Controlled Trial of the Efficacy of Systemic Enzymes and Probiotics in the Resolution of Post-COVID Fatigue. Medicines (Basel). 2021;8(9):47. https://doi.org/10.3390/medicines8090047..
DOI: 10.3390/medicines8090047
Heidari Z., Tajbakhsh A., Gheibihayat S.M., Moattari A., Razban V., Berenjian A. et al. Probiotics/Prebiotics in Viral Respiratory Infections: Implication for Emerging Pathogens. Recent Pat Biotechnol. 2021;15(2):112–136. https://doi.org/10.2174/1872208315666210419103742..
DOI: 10.2174/1872208315666210419103742